SCHEMBL5855374

SCHEMBL5855374

COC(=O)C(C)(C)OCCCCCCc1nc(-c2ccccc2)oc1C

nearest known ligand 0.82

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 18/20 0.82
PPARA Q07869 18/20 0.82
PPARD Q03181 5/20 0.82
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857695 1.00 PPARG (0.82) PPARGPPARAPPARDKDM4E
SCHEMBL5856037 1.00 PPARG (0.82) PPARGPPARAPPARDKDM4E
SCHEMBL5855701 0.92 PPARA (0.69) PPARGPPARAPPARD
SCHEMBL5856533 0.92 PPARA (0.69) PPARGPPARAPPARD
SCHEMBL5855571 0.91 PPARG (0.68) PPARGPPARAPPARDKDM4E
SCHEMBL5855953 0.90 PPARA (1.00) PPARGPPARAPPARD
SCHEMBL5858178 0.90 PPARA (1.00) PPARGPPARAPPARD
SCHEMBL5857062 0.90 PPARA (1.00) PPARGPPARAPPARD
SCHEMBL5857194 0.90 PPARA (0.66) PPARGPPARAPPARD
SCHEMBL5858400 0.90 PPARG (0.66) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP claimed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US claimed
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
CN-1238347-C Heterocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2006-01-25 CN disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
CN-1430612-A Hete rocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2003-07-16 CN disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB PPARG 393/4885PPARA 464/4885PPARD 912/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE PPARG 603/4885PPARA 579/4885PPARD 646/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885PPARD 875/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885PPARD 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.